{"id":"block_63b47bd4d6993","name":"acf\/block-rich-text-module","data":{"rich_text_module_0_content":"Boston, Massachusetts\u2013 PathAI, a global provider of artificial intelligence-powered technology for use in pathology research, announced today that it has secured an investment from LabCorp, a leading global life sciences company that is deeply integrated in guiding patient care through its comprehensive clinical laboratory and end-to-end drug development services. The investment signals a growing relationship between the companies, who are also collaborating on potential clinical applications for PathAI\u2019s technology. The relationship will support PathAI\u2019s efforts to expand clinical development of artificial intelligence-enabled computational pathology and advance its eventual integration with clinical laboratories.\r\n\r\n\u201cIt\u2019s great to have such a strong alliance with forward-thinking leaders in this industry like LabCorp,\u201d PathAI co-founder and Chief Executive Officer Andy Beck M.D., Ph.D., said. \u201cAs we continue to build on our early success in research toward faster and more accurate diagnosis and treatment of disease, our relationship with LabCorp could help bring these efforts to the market \u2013 and more importantly, to patients \u2013 more quickly and broadly.\u201d\r\n\r\n\u201cPathAI\u2019s technology is impressive, but more impressive has been PathAI\u2019s vision for the future of anatomic pathology,\u201d said Marcia Eisenberg, Ph.D., Chief Scientific Officer for LabCorp Diagnostics. \u201cBy working closely with companies like PathAI, we believe we can accelerate the promise of digital pathology and deliver faster and more accurate diagnoses, more effective treatments, and improved safety and outcomes for patients helping to fulfill our mission to improve health and improve lives.\u201d\r\nLabCorp\u2019s investment follows a $60 million round of funding into PathAI announced last month, led by global growth equity firm General Atlantic and venture capital firm General Catalyst. Further details about LabCorp\u2019s investment are not being disclosed.","rich_text_module_0_button":"","rich_text_module":1,"jump_link_label":""},"align":"","mode":"edit"}
Get In Touch
PathAI Media
Company Contact
Liz Storti
Chief People Officer
Media Contact
Daniel Donato
LifeSci Communications
516-474-0554